We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Idera Pharmaceuticals | AMEX:IDP | AMEX | Ordinary Share |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.00 | - |
Delaware | 04-3072298 | |
(State or Other Jurisdiction of | (I.R.S. Employer | |
Incorporation or Organization) | Identification No.) | |
167 Sidney Street | ||
Cambridge, Massachusetts | 02139 | |
(Address of Principal Executive Offices) | (Zip Code) |
Proposed | Proposed | |||||||||||||
Maximum | Maximum | Amount of | ||||||||||||
Title of Securities to be | Amount to be | Offering Price | Aggregate | Registration | ||||||||||
Registered | Registered(1) | Per Share | Offering Price | Fee | ||||||||||
Common Stock, $0.001 par
value per share
(including the
associated Preferred
Stock Purchase Rights)
|
1,500,000 shares | $11.94 (2) | $17,910,000 (2) | $550.00 | ||||||||||
(1) | In accordance with Rule 416 under the Securities Act of 1933, as amended, this registration statement shall be deemed to cover any additional securities that may from time to time be offered or issued to prevent dilution resulting from stock splits, stock dividends or similar transactions. | |
(2) | Estimated solely for the purpose of calculating the registration fee pursuant to Rules 457(c) and 457(h) of the Securities Act of 1933, as amended, and based upon the average of the high and low prices of the Registrants common stock as reported on the American Stock Exchange on November 14, 2007. |
- 1 -
Item 5. Interests of Named Experts and Counsel
Item 8. Exhibits
SIGNATURES
INDEX TO EXHIBITS
Table of Contents
Table of Contents
Idera Pharmaceuticals, Inc.
|
||||
By: | /s/ Sudhir Agrawal | |||
Sudhir Agrawal, D. Phil. | ||||
Chief Executive Officer | ||||
Signature | Title | Date | ||
/s/ James B. Wyngaarden
|
Chairman of the Board of Directors | November 16, 2007 | ||
/s/ Sudhir Agrawal
|
Chief Executive Officer, Chief Scientific Officer and Director (Principal Executive Officer) | November 16, 2007 | ||
/s/ Robert W. Karr
|
President and Director | November 16, 2007 | ||
/s/ Donna A. Lopolito
|
Interim Chief Financial Officer (Principal Financial and Accounting Officer) | November 16, 2007 | ||
/s/ Youssef El-Zein
|
Director | November 16, 2007 |
- 2 -
Signature | Title | Date | ||
/s/ C. Keith Hartley
|
Director | November 16, 2007 | ||
|
Director | |||
/s/ William S. Reardon
|
Director | November 16, 2007 | ||
/s/ Alison Taunton-Rigby
|
Director | November 16, 2007 |
- 3 -
EXHIBIT
NUMBER
DESCRIPTION
Rights Agreement dated December 10, 2001 between the Registrant and
Mellon Investor Services LLC, as rights agent.
Amendment No. 1 to Rights Agreement dated as of August 27, 2003
between the Registrant and Mellon Investor Services LLC.
Amendment No. 2 to Rights Agreement dated as of March 24, 2006
between the Registrant and Mellon Investor Services LLC.
Amendment No. 3 to Rights Agreement, dated as of January 16, 2007
between the Registrant and Mellon Investor Services LLC.
Opinion of Wilmer Cutler Pickering Hale and Dorr LLP.
Consent of Ernst & Young LLP.
Consent of Wilmer Cutler Pickering Hale and Dorr LLP, included in
Exhibit 5.1 filed herewith.
Power of Attorney (See signature page of this Registration Statement).
(1)
Previously filed with the Securities and Exchange Commission as an Exhibit to the
Registrants Registration Statement on Form S-2, dated October 10, 2003 (File No. 333-109630)
and incorporated herein by reference.
(2)
Previously filed with the Securities and Exchange Commission as an Exhibit to the
Registrants Current Report on Form 8-K, dated August 29, 2003 (File No. 000-27352) and
incorporated herein by reference.
(3)
Previously filed with the Securities and Exchange Commission as an Exhibit to the
Registrants Current Report on Form 8-K, dated March 29, 2006 (File No. 001-31918) and
incorporated herein by reference.
(4)
Previously filed with the Securities and
Exchange Commission as an Exhibit to the
Registrants Current Report on Form 8-K, dated
January 17, 2007 (File No. 001-31918) and
incorporated herein by reference.
1 Year Idera Pharmaceutical Chart |
1 Month Idera Pharmaceutical Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions